These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Endocannabinoid and endocannabinoid receptor antagonists]. Heinzl S Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333 [No Abstract] [Full Text] [Related]
5. Drug development. Drugs inspired by a drug. Marx J Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309 [No Abstract] [Full Text] [Related]
6. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. Ducobu J; Sternon J J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510 [TBL] [Abstract][Full Text] [Related]
7. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. Braakman HM; van Oostenbrugge RJ; van Kranen-Mastenbroek VH; de Krom MC Epilepsia; 2009 Sep; 50(9):2171-2. PubMed ID: 19706063 [No Abstract] [Full Text] [Related]
10. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Gelfand EV; Cannon CP Expert Opin Investig Drugs; 2006 Mar; 15(3):307-15. PubMed ID: 16503766 [TBL] [Abstract][Full Text] [Related]
11. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. Kintscher U Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715 [No Abstract] [Full Text] [Related]
12. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463 [TBL] [Abstract][Full Text] [Related]
13. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21. Alvarado M; Decara J; Luque MJ; Hernandez-Folgado L; Gómez-Cañas M; Gómez-Ruiz M; Fernández-Ruiz J; Elguero J; Jagerovic N; Serrano A; Goya P; de Fonseca FR Bioorg Med Chem; 2013 Apr; 21(7):1708-16. PubMed ID: 23434135 [TBL] [Abstract][Full Text] [Related]
14. [New obesity and metabolic syndrome treatment: rimonabant]. Makoundou V; Golay A Rev Med Suisse; 2006 Jan; 2(47):41-5. PubMed ID: 16465944 [TBL] [Abstract][Full Text] [Related]
16. Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant? Doggrell SA Expert Opin Investig Drugs; 2005 Mar; 14(3):339-42. PubMed ID: 15833065 [No Abstract] [Full Text] [Related]
17. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Patel PN; Pathak R Am J Health Syst Pharm; 2007 Mar; 64(5):481-9. PubMed ID: 17322160 [TBL] [Abstract][Full Text] [Related]
18. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy. Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179 [No Abstract] [Full Text] [Related]
19. Rimonabant: more than an anti-obesity drug? Costa B Br J Pharmacol; 2007 Mar; 150(5):535-7. PubMed ID: 17245359 [TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use. Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]